Merck & Co. Inc. (MRK) News
Filter MRK News Items
MRK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRK News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MRK News From Around the Web
Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.
Merck Insiders Sold US$6.4m Of Shares Suggesting HesitancyThe fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past... |
Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong FundamentalsWe recently published a list of Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks ahead of major AI event that Jim Cramer discussed. In his appearance on Squawk on the Street […] |
Medicare drug prices nearly double, surpassing inflation: AARPA new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly doubled in price since market entry, exceeding inflation trends. Yahoo Finance senior health reporter Anjalee Khemlani joins Brad Smith on Wealth to discuss the findings, highlighting significant cost increases for key medications, including Merck's (MRK) diabetes drug Janumet, soaring nearly 300% in its lifetime on the market dating back to 2007. While Medicare is beginning to negotiate prices, GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic are already seeing price increases since their debuts. To watch more expert insights and analysis on the latest market action, check out more Wealth! here. This post was written by Josh Lynch |
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency. |
Merck (NYSE:MRK) Has A Pretty Healthy Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that... |
Merck’s GARDASIL® Receives Expanded Approval for Males in ChinaRAHWAY, N.J., January 08, 2025--Merck’s GARDASIL® Receives Expanded Approval for Males in China |
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 MillionWuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties. |
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceRAHWAY, N.J., January 06, 2025--Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma DealLast Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH). Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity. The recommended dosing schedule is one injection every three weeks via self-administration. Also Read: Big Biopharma Trails Behind The Market |
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on ItRecently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store. |